Skip to content

Assessment of the Therapeutic Efficacy of NBS in Managing Liver Cirrhosis

Investigating the effect of Nutrition Bio-Shield (NBS) herbal supplement on liver function and complications in patients with liver cirrhosis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20241218064090N3
Enrollment
74
Registered
2025-08-10
Start date
2025-09-06
Completion date
Unknown
Last updated
2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis. Other and unspecified cirrhosis of liver

Interventions

Intervention 1: Intervention group: The intervention will involve the consumption of the NBS dietary supplement for a duration of three months. The herbal NBS supplement will be administered to the in

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 65 years Documented diagnosis of liver cirrhosis in the patient’s medical records Ability to provide written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Use of any other dietary supplements by the patient Presence of uncontrolled clinical or biochemical complications related to severe liver failure (hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, serum bilirubin level greater than 5 mg/dL) History of hepatocellular carcinoma History of active alcoholism History of drug allergy or gluten sensitivity Women who are pregnant or breastfeeding during the study period Individuals with immunosuppressive diseases or taking immunosuppressive medications Individuals with autoimmune diseases History of infection within the past 3 months

Design outcomes

Primary

MeasureTime frame
Liver function. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Clinical symptoms, laboratory tests, imaging methods, and biopsy and histopathology.

Secondary

MeasureTime frame
Body Mass Index (BMI). Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Weight measured using a scale and height measured using a stadiometer.;Skeletal Muscle Index (SMI). Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: Body analyzer device and formula.;Sarcopenia. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: hand grip strength meter.;Oxidative stress. Timepoint: Before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Jafari

Tehran University of Medical Sciences

maryamjafari.mj.99@gmail.com+98 21 6105 4000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026